NCT07066631 The Pregnancy and Postpartum Mental Health Optimization Virtual Intervention Network
| NCT ID | NCT07066631 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Women's College Hospital |
| Condition | Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 570 participants |
| Start Date | 2025-10-29 |
| Primary Completion | 2028-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 570 participants in total. It began in 2025-10-29 with a primary completion date of 2028-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Depression, anxiety, and related disorders such as post-traumatic stress and obsessive compulsive disorder affect about 20% of pregnant and postpartum people. When not treated properly, these issues negatively impact not only affected people, but also their children's health and development. Only 1 in 5 receive adequate treatment, so identifying new system-wide approaches to reliably deliver recommended care to perinatal mental health patients all is a crucial health care priority. The Pregnancy and Postpartum Mental health Optimization Virtual Intervention Network (MOVIN) is a scalable perinatal mental health platform building on the evidence-based Collaborative care delivery model. MOVIN's online platform allows patients to connect with a care coordinator to co-develop personalized treatment recommendations, in collaboration with their primary care clinician and a perinatal psychiatrist when needed; progress is tracked to re-evaluate.
Eligibility Criteria
Inclusion Criteria: 1. Adult (age 18 years or older) 2. Pregnant or postpartum and living with their infant 0-6 months old. This includes all individuals who identify as women, as well as those of female sex who do not identify as women (e.g., non-binary, trans) who are the primary parent for their infant. This includes via natural birth, adoption, or surrogacy. 3. EPDS score \>10 at eligibility screening. Exclusion Criteria: 1. Active alcohol or substance use disorder, mania or psychotic disorder (as these conditions are better managed in direct specialty care). 2. Active suicide plan or intent (as emergent hospital-based care is likely required), 3. Plan to move out of Ontario during the study. 4. Unable to complete relevant study procedures and measures online. For the few participants without access to devices/home internet, we will budget for tablets/data plans. 5. Unable to complete study activities in English. Note that Google translate is available for the intervention platform and language lines are available for participants so that they can be served in their language of choice, however we are unable to provide translations of all study assessment and questionnaire materials that participants will need to complete during the study. 6. No primary care clinician (required for collaborative mental health care delivery model). 7. Currently enrolled in a collaborative mental health care model.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07066631 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07066631 currently recruiting?
Yes, NCT07066631 is actively recruiting participants. Contact the research team at simone.vigod@wchospital.ca for enrollment information.
Where is the NCT07066631 trial being conducted?
This trial is being conducted at Toronto, Canada, Toronto, Canada.
Who is sponsoring the NCT07066631 clinical trial?
NCT07066631 is sponsored by Women's College Hospital. The trial plans to enroll 570 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.